pubrio
Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

Public
alnylam.com
生物技术研究2,600+ employeesFounded 2002🇺🇸 美国

SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email [email protected] or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861 Fraudulent Recruitment Activity Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."

成立年份
2002
员工人数
2,600+
行业
生物技术研究
公司类型
Public Company
股票
nasdaq: ALNY
总部
🇺🇸Cambridge, Massachusetts (+8)
专长
研究行业制药行业生物技术医疗保健生物技术研究
5 / 11
活跃市场
2
新市场
FR · IN
置信度
多为早期信号
0%
势头
较上一周期
33 / 100
扩张评分
发展中
阶段1探索中10投入中
6 个信号 · 最近 90 天

全球扩张

实时
GBDECH
阶段
探索中投入中进入中运营中
+8个市场已锁定
已显示 11 个中的 3 个

解锁市场时间线与信号动态

活动脉搏

最近 90 天内有 6 个信号。

最近 90 天
招聘
6↑ +100%
招聘
营销与公关
0
无活动
产品与技术
0
无活动
+2个类别已锁定
已显示 5 个中的 3 个

市场进入时间线

该公司进入各个市场的顺序 — 从最早到最新

1
🇬🇧GB进入的第 1st 个市场 · 2022推进中
投入中
24 个信号投入中 阶段
2
🇩🇪DE进入的第 2nd 个市场 · 2024推进中
投入中
21 个信号投入中 阶段
3
🇨🇭CH进入的第 3rd 个市场 · 2025推进中
投入中
11 个信号投入中 阶段
+8个市场已锁定
已显示 11 个中的 3 个
当前阶段投入中投入资源
置信度35%
开始追踪于2022首个信号

近期信号

招聘🇮🇹 IT2周前

Sr Manager, Medical Science Liaison - LOMBARDIA EST / TRIVENETO

招聘🇨🇭 CH上个月

Director, Medical Affairs

注册以查看完整信号动态

了解一下

关于 Alnylam Pharmaceuticals 的常见问题

关于 Alnylam Pharmaceuticals 的业务、市场和增长信号的快速解答。

SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email [email protected] or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861 Fraudulent Recruitment Activity Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."

今天就开启旅程

可以先用平台,也可以先聊聊

你可以自行使用 Pubrio,或让我们的团队协助研究、获客或数据整合。

与团队沟通
Start Journey Image
pubrio

Pubrio 将来自 50+ 本地来源的商业、人物与意向数据整合为全球图谱,帮助 AI 与营收团队洞悉全市场。

© 2026 Pubrio。保留所有权利。